Concomitant serious immunocompromised status (other than that related to concomitant steroids) that would compromise the safety of the patient on the study
Use of protocol-defined prior/concomitant therapy.
Concomitant medication restrictions:
Concomitant medication restrictions
Uncontrolled concomitant disease
Concomitant second malignancies
Previous and concomitant therapy that precludes enrollment, as defined in the protocol
Subjects with concomitant second malignancies
Have a serious concomitant systemic disorder.
Use of protocol-defined prior/concomitant therapy.
Patients receiving any concomitant systemic therapy for renal cell cancer are excluded.
Uncontrolled concomitant disease
Uncontrolled concomitant disease
Serious concomitant systemic disorder.
Patients receiving any concomitant systemic therapy for renal cell cancer are excluded
Concomitant illness associated with a likely survival of <  year
Have a serious concomitant systemic disorder.
Presence of any serious or unstable concomitant systemic disorder incompatible with the clinical study
Concomitant illness associated with a likely survival of <  year
Anticipated need for concomitant administration of any other experimental drug, or a concomitant chemotherapy, anticancer hormonal therapy, radiotherapy, or immunotherapy during study participation.
Concomitant illness associated with a likely survival of <  year
Uncontrolled concomitant disease
Concomitant therapies for treatment or control of leukemia.
Serious uncontrolled concomitant systemic disorders or psychiatric condition that would interfere with the safe delivery of protocol therapy
Other serious uncontrolled concomitant systemic disorders or psychiatric condition that would interfere with the safe delivery of protocol therapy
Concomitant use of anthracyclines or use of anthracyclines in the last  days
Patients must be free of other active systemic malignancy, ongoing infection, or any other serious uncontrolled, concomitant systemic disorders or psychiatric condition that would interfere with the safe delivery of protocol therapy
Prior or concomitant systemic anti-cancer treatment for advanced disease
Enrollment in a concomitant clinical study
Planned concomitant participation in another clinical trial of an experimental agent, vaccine, or device. Concomitant participation in observational studies is acceptable.
Must not require concomitant treatment with anticoagulants
Concomitant illness associated with a likely survival of <  year
Requirement for any non-study potentially effective concomitant systemic antibacterial therapy
Concomitant radiotherapy
Presence of any serious or unstable concomitant systemic disorder incompatible with\n             the clinical study
Prior/Concomitant Therapy
Concomitant severe or uncontrolled medical disease
Presence of any serious or unstable concomitant systemic disorder incompatible with the clinical study
Use of protocol-defined prior/concomitant therapy.
Other concomitant malignancies (with some exceptions per protocol)
Other concomitant malignancies (with some exceptions per protocol)
Any concomitant systemic therapy or radiation therapy initiated for this malignancy.
Evidence of any significant, uncontrolled concomitant disease
Use of protocol-defined prior/concomitant therapy.
Use of protocol-defined prior/concomitant therapy.
Use of protocol-defined prior/concomitant therapy.
Use of protocol-defined prior/concomitant therapy.
Concomitant treatment with:
Plans for the patient to receive other concomitant local therapy (including standard fractionated radiotherapy and surgery) while on this protocol except at disease progression
Concomitant use of antithrombotic agents with the exception of platelet inhibitors.
Concomitant malignancies
Patients must be able to follow concomitant medication restrictions:
Previous or concomitant malignancies at any other site with the exception of the following:
Evidence of significant, uncontrolled concomitant disease
Concomitant illness associated with a likely survival of <  year
Patients who are undergoing concomitant radiotherapy are NOT eligible for participation
Patients must not receive concomitant radiation
Have a serious concomitant systemic disorder or significant cardiac disease.
There must be no plans to receive concomitant chemotherapy, biological response modifiers, radiation therapy or hormonal therapy; concomitant radiation therapy is allowed for the palliation of severe pain/neuropathic compression
Concomitant therapy that precludes enrollment, as defined in the protocol
Patients who are undergoing concomitant radiotherapy are NOT eligible for participation
Patients with concomitant disease know to get influence on bone metabolism
Any other concomitant anti-cancer treatment.
Serious concomitant systemic disorder
Concomitant use of any type of anti-cancer treatment other than studied in the parent protocol.
Current concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in the protocol; concomitant use of corticosteroids is permitted as clinically indicated
Concomitant use of foscarnet, liposomal amphotericin B or aminoglycoside
Concomitant malignancy;
Unfit for Surgery: serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator);
Presence of any serious or unstable concomitant systemic disorder incompatible with the clinical study
Other concomitant anticancer treatment
Serious concomitant conditions
Subject requires the use of the following concomitant treatments/procedures at any time, per protocol.
Concomitant use of phosphodiesterase inhibitors
Received concomitant Temozolomide
Patients who are receiving concomitant systemic therapy for breast cancer
Other concomitant anti-tumor therapy as determined by the study team.
Serious concomitant systemic disorders
Other concomitant malignancies (with some exceptions per protocol)
Concomitant chemotherapy or radiotherapy is not permitted.
Concomitant illness associated with a likely survival of <  year
Other concomitant malignancies (with some exceptions per protocol)
Any concomitant disease or condition which would interfere with the subjects' proper completion of the protocol assignment.
Concomitant illness associated with a likely survival of <  year
Known concomitant disease(s) known to influence calcium metabolism including hyperparathyroidism, hyperthyroidism, Paget's disease of bone, or any other concurrent severe or uncontrolled concomitant medical condition that, in the opinion of the Investigator, would preclude participation in this study
Other active concomitant malignancy that warrants systemic therapy
Other active concomitant malignancy that warrants systemic therapy
Concomitant severe or uncontrolled medical disease
For patients enrolled into Stage I, they must have received at least % of planned radiotherapy ( Gy) with temozolomide treatment during the concomitant phase have documentation that the patient's absolute neutrophil count (ANC) is ? . x /L, platelet count is ?  x /L, and there was no CTC grade  or above nonhematological toxicity (except for alopecia, nausea, vomiting) during the concomitant phase treatment be within ?  weeks but ?  weeks following the completion of temozolomide in the concomitant phase
Concomitant chemotherapy or radiotherapy is not permitted.
Concomitant enrollment in a Phase I study
NOTE: concomitant treatment with ongoing trastuzumab (Herceptin) or other targeted/biologic agents is allowed; concomitant treatment with any other type of chemotherapy or hormonal therapy is not allowed
Concomitant malignancies
There must be no plans for the patient to receive other concomitant therapy while on this protocol treatment (other than sandostatin or BIS-phosphonate therapy)
Subjects with chronic kidney disease or concomitant parathyroid disease
No other concomitant therapy directed at the cancer is allowed
Patients undergoing concomitant colectomy
Concomitant panniculectomy or plastic surgery
Severe concomitant illnesses
Concomitant use of oral cyclosporine
Women who are receiving any other concomitant treatment for their DCIS/ADH
Concomitant corticosteroids or anticoagulants needed on a regular or predictable intermittent basis
Severe concomitant illnesses
No concomitant infection or other serious major systemic illness
Concomitant cyclosporine, gemfibrozil, telaprevir, or tipranavir/ritonavir use
Other concomitant malignancies (with some exceptions per protocol)
Co-medication or concomitant therapy that may interfere with study results
